Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells

Molecular Pharmacology

Volumn 72, Issue 1, 2007, Pages 73-85

  Xie, Yan ^a   Wolff, Dennis W ^a   Lin, Ming Fong ^b   Tu, Yaping ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CANCER GROWTH; CELL GROWTH; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; WILD TYPE;

ACTIVE TRANSPORT, CELL NUCLEUS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; PROSTATIC NEOPLASMS; RAP1 GTP-BINDING PROTEINS; RECEPTORS, ANDROGEN; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; VASOACTIVE INTESTINAL PEPTIDE;

EID: 34347227789     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.033894     Document Type: Article

References (40)

1. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC, and Rowley D (2004) Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 64:6082-6090.
2. Bos JL (2003) EPAC: a new cAMP target and new avenues in cAMP research. Nat Rev Mol Cell Biol 4:733-738.
3. Buhlmann N, Leuthauser K, Muff R, Fischer JA, and Born W (1999) A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1. Endocrinology 140:2883-2890.
4. Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M, Lin MF, and Tu Y (2006) Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene 25:3719-3734.
5. Chen T, Cho RW, Stork PJ, and Weber MJ (1999) Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res 59:213-218.
6. Christensen AE, Selheim F, de Rooij J, Dremier S, Schwede F, Dao KK, Martinez A, Maenhaut C, Bos JL, Genieser HG, et al. (2003) CAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and CAMP kinase act synergistically to promote PC-12 cell neurite extension. J Biol Chem 278:35394-35402.
7. Collado B, Carmena MJ, Sanchez-Chapado M, Ruiz-Villaespesa A, Bajo AM, Fernandez-Martinez AB, Varga JL, Schally AV, and Prieto JC (2005) Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int J Oncol 26:1629-1635.
8. Daaka Y (2004) G proteins in cancer: the prostate cancer paradigm. Sci STKE 2004:re2.
9. Enserink JM, Christensen AE, de Rooij J, van Treist M, Schwede F, Genieser HG, Doskeland SO, Blank JL, and Bos JL (2002) A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat Cell Biol 4:901-906.
10. Feldman BJ and Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
11. Fernández M, Sanchez-Franco F, Palacios N, Sanchez I, and Cacicedo L (2005) IGF-I and vasoactive intestinal peptide (VIP) regulate cAMP-response element-binding protein (CREB)-dependent transcription via the mitogen-activated protein kinase (MAPK) pathway in pituitary cells: requirement of Rap1. J Mol Endocrinol 34:699-712.
12. Fizanne L, Sigaudo-Roussel D, Saumet JL, and Fromy B (2004) Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents. J Physiol 554:519-528.
13. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, and Abate-Shen C (2006) Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A 103:14477-14482.
14. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, and Weber MJ (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59:279-284.
15. Gkonos PJ, Guo F, and Burnstein KL (2000) Type 1 vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation. Prostate 42:137-144.
16. Gotoh T, Hattori S, Nakamura S, Kitayama H, Noda M, Takai Y, Kaibuchi K, Matsui H, Hatase O, Takahashi H, et al. (1995) Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Mol Cell Biol 15:6746-6753.
17. Gutiérrez-Cañas I, Juarranz MG, Collado B, Rodriguez-Henche N, Chiloeches A, Prieto JC, and Carmena MJ (2005) Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. Prostate 63:44-55.
18. Heinlein CA and Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276-308.
19. Iacovelli L, Capobianco L, Salvatore L, Sallese M, D'Ancona GM, and De Blasi A (2001) Thyrotropin activates mitogen-activated protein kinase pathway in FRTL-5 by a cAMP-dependent protein kinase A-independent mechanism. Mol Pharmacol 60:924-933.
20. s signaling in prostate cancer cells. J Biol Chem 280:11583-11589.
21. Kashiba H, Senba E, Ueda Y, and Tohyama M (1992) Co-localized but target-unrelated expression of vasoactive intestinal polypeptide and galanin in rat dorsal root ganglion neurons after peripheral nerve crush injury. Brain Res 582:47-57.
22. Lee LF, Guan J, Qiu Y, and Kung HJ (2001) Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 21:8385-8397.
23. Maucher A and von Angerer E (1993) Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumors. J Cancer Res Clin Oncol 119:669-674.
24. Nelson JB (2003) Endothelin inhibition: novel therapy for prostate cancer. J Urol 170:S65-S67.
25. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, et al. (1998) Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 4:50-57.
26. Polak JM and Bloom SR (1984) Localization and measurement of VIP in the genitourinary system of man and animals. Peptides 5:225-230.
27. Rekasi Z, Varga JL, Schally AV, Halmos G, Armatis P, Groot K, and Czompoly T (2000) Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. Endocrinology 141:2120-2128.
28. Rochette-Egly C (2003) Nuclear receptors: integration of multiple signaling pathways through phosphorylation. Cell Signal 15:355-366.
29. Sastry KS, Smith AJ, Karpova Y, Datta SR, and Kulik G (2006) Diverse antiapoptotic signaling pathways activated by VIP, EGF and PI3K in prostate cancer cells converge on BAD. J Biol Chem 281:20891-20901.
30. Schmitt JM and Stork PJ (2002) PKA phosphorylation of Src mediates cAMP's inhibition of cell growth via Rap1. Mol Cell 9:85-94.
31. 2+ transients. Endocrinology 134:596-602.
32. Shi S, Noda M, and Kitayama H (2004) Rap1 mutants with increased affinity for the guanine-nucleotide exchange factor C3G. Oncogene 23:8711-8719.
33. Stork PJ and Schmitt JM (2002) Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12:258-266.
34. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, et al. (2003) Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group B study 9663. J Clin Oncol 21:2673-2678.
35. s/mitogen-activated protein kinase pathway in mutant S49 cells. J Biol Chem 273:14533-14537.
36. Wang Z, Dillon TJ, Pokala V, Mishra S, Labudda K, Hunter B, and Stork PJ (2006) Rap1-mediated activation of extracellular signal-regulated kinases by cyclic AMP is dependent on the mode of Rap1 activation. Mol Cell Biol 26:2130-2145.
37. Xu BE, Stippec S, Robinson FL, and Cobb MH (2001) Hydrophobic as well as charged residues in both MEK1 and ERK2 are important for their proper docking. J Biol Chem 276:26509-26515.
38. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, and Chang C (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 96:5458-5463.
39. Zegarra-Moro OL, Schmidt LJ, Huang H, and Tindall DJ (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013.
40. Zhou ZX, Kemppainen JA, and Wilson EM (1995) Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol 9:605-615.